SAN ANTONIO — The benefit of adding abemaciclib to adjuvant endocrine therapy for certain patients with high-risk breast cancer deepened with time ...
News
- Longer follow-up supports benefit of abemaciclib for high-risk breast cancer - Healio
- Metastasis 'Doorway' May Lead to Racial Disparities in Breast Cancer | MedPage Today
SAN ANTONIO -- Black patients with certain types of breast cancer treated with chemotherapy had increased concentrations of a cellular complex ...
- Kisqali Outperforms Combination Chemo in Aggressive HR-Positive, HER2-Negative Breast Cancer
SAN ANTONIO – A Phase II trial of Novartis' CDK4/6 inhibitor Kisqali (ribociclib) plus endocrine therapy showed improvement in progression-free ...
- First-Line CDK4/6 Thumps Chemo in Aggressive, Advanced Breast Cancer
SAN ANTONIO -- A CDK4/6 inhibitor plus endocrine therapy combination ... Pfizer, Seagen, Daiichi Sankyo, Puma Biotechnology, and Novartis.
- Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio ...
... Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.